Antifungal therapy update: New drugs and medical uses;Actualización en terapia antifúngica: nuevos fármacos e indicaciones

Enfermedades Infecciosas y Microbiologia Clinica

Volumn 29, Issue SUPPL. 5, 2011, Pages 38-44

  Fortún, Jesús ^a  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

Author keywords

Antifungal therapy; Invasive fungal infections; Update

Indexed keywords

ANTIFUNGAL AGENT;

ANTIFUNGAL ACTIVITY; ARTICLE; ASPERGILLUS; CANDIDA; CLINICAL EFFECTIVENESS; CRYPTOCOCCUS; DRUG EFFICACY; DRUG SAFETY; FUSARIUM; MYCOSIS; NONHUMAN; SCEDOSPORIUM; ZYGOMYCETES;

ANTIFUNGAL AGENTS; ASPERGILLOSIS; CANDIDIASIS; CLINICAL TRIALS AS TOPIC; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; EARLY DIAGNOSIS; ECHINOCANDINS; HUMANS; IMMUNOCOMPROMISED HOST; LIPOPEPTIDES; MYCOSES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SALVAGE THERAPY; TREATMENT OUTCOME; TRIAZOLES;

EID: 84856599022     PISSN: 0213005X     EISSN: 15781852     Source Type: Journal    
DOI: 10.1016/S0213-005X(11)70042-8     Document Type: Article

References (91)

1. D. Neofytos, D. Horn, E. Anaissie, W. Steinbach, A. Olyaei, and J. Fishman Epidemiology and outcome of invasive fungal infection in adult haematopoietic stem cell transplant recipients: analysis of multicentre Prospective Antifungal Therapy (PATH) Alliance registry Clin Infect Dis 48 2009 265 273
2. P.G. Pappas, B.D. Alexander, D.R. Andes, S. Hadley, C.A. Kauffman, and A. Freifeld Invasive fungal infections among organ transplant recipients: results of the transplant-associated infection surveillance network (TRANSNET) Clin Infect Dis 50 2010 1101 1111
3. M.D. Zilberberg, A.F. Shorr, and M.H. Kollef Secular trends in candidemia-related hospitalization in the United States, 2000-2005 Infect Control Hosp Epidemiol 29 2008 978 980
4. O. Leroy, J.-P. Gangneux, P. Montravers, J.-P. Mira, F. Gouin, J. Sollet AmarCand Study Group: Epidemiology, management, and risk factors for death of invasive Candida infections in critical care: a multicenter, prospective, observational study in France (2005-2006) Crit Care Med 37 2009 1612 1618
5. K.W. Garey, M. Rege, M.P. Pai, D.E. Mingo, K.J. Suda, and R.S. Turpin Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multiinstitutional study Clin Infect Dis 43 2006 25 31 (Pubitemid 43939072)
6. J.M. Aguado, I. Ruiz-Camps, P. Muñoz, J. Mensa, B. Almirante, L. Vázquez Grupo de Estudio de Micología Médica de la SEIMC (GEMICOMED) Guidelines for the treatment of invasive candidiasis and other yeasts. Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC). 2010 Update Enferm Infecc Microbiol Clin 29 2011 345 361
7. P.G. Pappas, C.A. Kauffman, D. Andes, D.K. Benjamin, T.F. Calandra, and J.E. Edwards Clinical practice guidelines for the management of candidiasis: 2009 Update by the Infectious Diseases Society of America Clin Infect Dis 48 2009 503 535
8. I. Lee, N.O. Fishman, T.E. Zaoutis, K.H. Morales, M.G. Weiner, and M. Synnestvedt Risk factors for fluconazole-resistant Candida glabrata bloodstream infections Arch Int Med 169 2009 379 383
9. S.S. Magill, C. Shields, C.L. Sears, M. Choti, and W.G. Merz Triazole Cross-Resistance among Candida spp.: case report, occurrence among bloodstream isolates, and implications for antifungal therapy J Clin Microbiol 44 2006 529 535 (Pubitemid 43222248)
10. J.H. Rex, J.E. Bennett, A.M. Sugar, P.G. Pappas, C.M. Van der Horst, and J.E. Edwards A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia N Engl J Med 331 1994 1325 1330 (Pubitemid 24347001)
11. B.J. Kullberg, J.D. Sobel, M. Ruhnke, P.G. Pappas, C. Viscoli, and J.H. Rex Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in nonneutropenic patients: a randomised non-inferiority trial Lancet 366 2005 1435 1442 (Pubitemid 41483809)
12. W.W. Hope, E.M. Billaud, J. Lestner, and D.W. Denning Therapeutic monitoring for triazoles Curr Opin Infect Dis 21 2008 580 586
13. T.J. Walsh, P. Pappas, D.J. Winston, H.M. Lazarus, F. Petersen, and J. Raffalli Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever N Engl J Med 346 2002 225 234 (Pubitemid 34438861)
14. J. Mora-Duarte, R. Betts, C. Rotstein, A.L. Colombo, L. Thompson-Moya, J. Smietana Caspofungin Invasive Candidiasis Study Group Comparison of caspofungin and amphotericin B for invasive candidiasis N Engl J Med 347 2002 2020 2029 (Pubitemid 35461658)
15. E.R. Kuse, P. Chetchotisakd, C.A. Da Cunha, M. Ruhnke, C. Barrios, D. Raghunadharao Micafungin Invasive Candidiasis Working Group Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial Lancet 369 2007 1519 1527 (Pubitemid 46670281)
16. P.G. Pappas, C.M. Rotstein, R.F. Betts, M. Nucci, D. Talwar, and J.J. De Waele Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis Clin Infect Dis 45 2007 883 893 (Pubitemid 47580382)
17. A.C. Reboli, C. Rotstein, P.G. Pappas, S.W. Chapman, D.H. Kett, D. Kumar Anidulafungin Study Group Anidulafungin versus fluconazole for invasive candidiasis N Engl J Med 356 2007 2472 2482 (Pubitemid 46919773)
18. R.F. Betts, M. Nucci, D. Talwar, M. Gareca, F. Queiroz-Telles, and R.J. Bedimo A multicenter, double-blind trial of a high-dose caspofungin treatment regimen versus a standard caspofungin treatment regimen for adult patients with invasive candidiasis Clin Infect Dis 48 2009 1676 1684
19. A.L. Colombo, A.L. Ngai, M. Bourque, S.K. Bradshaw, K.M. Strohmaier, and A.F. Taylor Caspofungin use in patients with invasive candidiasis caused by common nonalbicans Candida species: review of the caspofungin database Antimicrob Agents Chemother 54 2010 1864 1871
20. T.E. Zaoutis, H.S. Jafri, L.M. Huang, F. Locatelli, A. Barzilai, and W. Ebell A prospective multicenter study of caspofungin for the treatment of documented Candida or Aspergillus infections in pediatric patients Pediatrics 123 2009 877 884
21. C. Sanz-Rodríguez, R. Arranz, J.M. Cisneros, P.J. García-Sánchez, M. Jurado, and J. López Absence of clinically relevant effect of caspofungin oncyclosporin pharmacokinetics Swiss Med Wkly 135 2005 658 659 (Pubitemid 41811598)
22. M. Winkler, J. Pratschke, U. Schulz, S. Zheng, M. Zhang, and W. Li Caspofunginfor post solid organ transplant invasive fungal disease: results of a retrospective observational study Transpl Infect Dis 12 2010 230 237
23. F. Queiroz-Telles, E. Berezin, G. Leverger, A. Freire, A. Van der Vyver, and T. Chotpitaya- Sunondh Micafungin versus liposomal amphotericin B for pediatric patients with invasive candidiasis: substudy of a randomized double-blind trial Pediatr Infect Dis J 27 2008 820 826
24. M.F. Hebert, R.W. Townsend, S. Austin, G. Balan, D.K. Blough, and D. Buell Concomitant cyclosporine and micafungin pharmacokinetics in healthy volunteers J Clin Pharmacol 45 2005 954 960 (Pubitemid 41060236)
25. M.F. Hebert, D.K. Blough, R.W. Townsend, M. Allison, D. Buell, and J. Keirns Concomitant tacrolimus and micafungin pharmacokinetics in healthy volunteers J Clin Pharmacol 45 2005 1018 1024 (Pubitemid 41192360)
26. L. Ostrosky-Zeichner, D. Kontoyiannis, J. Raffalli, K.M. Mullane, J. Vázquez, and E.J. Anaissie International, open-label, noncomparative, clinical trial of micafungin alone and in combination for treatment of newly diagnosed and refractory candidemia Eur J Clin Microbiol Infect Dis 24 2005 654 661 (Pubitemid 41667052)
27. G.N. Forrest, F. Rasetto, G. Akpek, and B. Philosophe Safety and efficacy of micafungin in transplantation recipients Transplantation 82 2006 1549 (Pubitemid 44967644)
28. E. Cateau, M.H. Rodier, and C. Imbert In vitro efficacies of caspofungin or micafungin catheter lock solutions on Candida albicans biofilm growth J Antimicrob Chemother 62 2008 153 155 (Pubitemid 351865889)
29. B.D. Brielmaier, E. Casabar, C.M. Kurtzeborn, P.S. McKinnon, and D.J. Ritchie Early clinical experience with anidulafungin at a large tertiary care medical center Pharmacotherapy 28 2008 64 73
30. J.A. Dowell, M. Stogniew, D. Krause, T. Henkel, and I.E. Weston Assessment of the safety and pharmacokinetics of anidulafungin when administered with cyclosporine J Clin Pharmacol 45 2005 227 233 (Pubitemid 40490447)
31. J.A. Dowell, M. Stogniew, D. Krause, T. Henkel, and B. Damle Lack of pharmacokinetici nteraction between anidulafungin and tacrolimus J Clin Pharmacol 47 2007 305 314 (Pubitemid 46294710)
32. T.J. Walsh, H. Teppler, G.R. Donowitz, J.A. Maertens, L.R. Baden, and A. Dmoszynska Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia N Engl J Med 351 2004 1391 1402
33. G. García-Effron, S. Park, and D.S. Perlin Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: implications for interpretive breakpoints Antimicrob Agents Chemother 53 2009 112 122
34. L. Ostrosky-Zeichner, K.A. Marr, J.H. Rex, and S.H. Cohen Amphotericin B: time for a new "gold standard" Clin Infect Dis 37 2003 415 425 (Pubitemid 36976501)
35. K. Hirata, T. Aoyama, Y. Matsumoto, F. Ogawa, H. Yamazaki, and A. Kikuti Pharmacokinetics of antifungal agent micafungin in critically ill patients receiving continuous hemodialysis filtration Yakugaku Zasshi 127 2007 897 901 (Pubitemid 46684737)
36. O. Burkhardt, V. Kaever, H. Burhenne, and J.T. Kielstein Extended daily dialysis does not affect the pharmacokinetics of anidulafungin Int J Antimicrob Agents 34 2009 282 283
37. J.L. Wang, C.H. Chang, Y. Young-Xu, and K.A. Chan Systematic review and meta-analysis of the tolerability and hepatotoxicity ofantifungals in empirical and definitive therapy for invasive fungal infection Antimicrob Agents Chemother 54 2010 2409 2419
38. P.E. Verweij, E. Mellado, and W.J. Melchers Multiple-triazole-resistant aspergillosis N Engl J Med 356 2007 1481 1483
39. E. Snelders, R.A. Huis In't Veld, A.J. Rijs, G.H. Kema, W.J. Melchers, and P.E. Verweij Possible environmental origin of resistance of Aspergillus fumigatus to medical triazoles Appl Environ Microbiol 75 2009 4053 4057
40. M.C. Arendrup, E. Mavridou, K.L. Mortensen, E. Snelders, M. Frimodt, and N. ller Development of azole resistance in Aspergillus fumigatus during azole therapy associated with change in virulence PLoS One 5 2010 e10080
41. T.J. Walsh, E.J. Anaissie, D.W. Denning, R. Herbrecht, D.P. Kontoyiannis, and K.A. Marr Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America Clin Infect Dis 46 2008 327 360 (Pubitemid 351265310)
42. J. Fortún, J. Carratalá, J. Gavaldá, M. Lizasoain, M. Salavert, R. De la Cámara Grupo de Estudio de Micología Médica de la SEIMC (GEMICOMED) Guidelines for the treatment of invasive fungal disease by Aspergillus spp. and other fungi issued by the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC). 2011 Update Enferm Infecc Microbiol Clin 29 2011 435 454
43. R. Herbrecht, D.W. Denning, T.F. Patterson, J.E. Bennett, R.E. Greene, and J.W. Oestmann Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis N Engl J Med 347 2002 408 415 (Pubitemid 34851833)
44. O.A. Cornely, J. Maertens, M. Bresnik, R. Ebrahimi, A.J. Ullmann, and E. Bouza Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial) Clin Infect Dis 44 2007 1289 1297 (Pubitemid 46717290)
45. C. Viscoli, R. Herbrecht, H. Akan, L. Baila, A. Sonet, and A. Gallamini An EORTC Phase II study of caspofungin as first-line therapy of invasive aspergillosis in haematological patients J Antimicrob Chemother 64 2009 1274 1281
46. R. Herbrecht, J. Maertens, L. Baila, M. Aoun, W. Heinz, and R. Martino Caspofungin first-line therapy for invasive aspergillosis in allogeneic hematopoietic stem cell transplant patients: an European Organisation for Research and Treatment of Cancer study Bone Marrow Transplant 45 2010 1227 1233
47. J. Maertens, I. Raad, G. Petrikkos, M. Boogaerts, D. Selleslag, and F.B. Petrsen Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy Clin Infect Dis 39 2004 1563 1571 (Pubitemid 39578526)
48. T.J. Walsh, I. Raad, T.F. Patterson, P. Chandrasekar, G.R. Donowitz, and R. Graybill Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial Clin Infect Dis 44 2007 2 12 (Pubitemid 44968977)
49. D.P. Kontoyiannis, V. Ratanatharathorn, J.A. Young, J. Raymond, M. Laverdiere, and D.W. Denning Micafungin alone or in combination with other systemic antifungal therapies in hematopoietic stem cell transplant recipients with invasive aspergillosis Transpl Infect Dis 11 2009 89 93
50. D. Caillot Intravenous itraconazole followed by oral itraconazole for the treatment of amphotericin-B-refractory invasive pulmonary aspergillosis Acta Haematol 109 2003 111 118 (Pubitemid 36506370)
51. K.A. Marr, M. Boeckh, R.A. Carter, H.W. Kim, and L. Corey Combination antifungal therapy for invasive aspergillosis Clin Infect Dis 39 2004 797 802 (Pubitemid 39244292)
52. N. Singh, A.P. Limaye, G. Forrest, N. Safdar, P. Muñoz, and K. Pursell Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients: a prospective, multicenter, observational study Transplantation 81 2006 320 326 (Pubitemid 43255714)
53. D. Caillot, T.A. Thiebaut, R. Herbrecht, S. Botton, A. Pigneux, and F. Bernard Liposomal amphotericin B in combination with caspofungin for invasive aspergillosis in patients with hematologic malignancies: a randomized pilot study (COMBISTRAT trial) Cancer 110 2007 2740 2746 (Pubitemid 350250344)
54. L. Ostrosky-Zeichner Combination antifungal therapy: a critical review of the evidence Clin Microbiol Infect 14 Suppl 4 2008 65 70 (Pubitemid 351593918)
55. J. Maertens, O. Marchetti, R. Herbrecht, O.A. Cornely, U. Fluckiger, and P. Frere European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3-2009 Update Bone Marrow Transplant 46 2011 709 718
56. A.H. Saad, D.D. DePestel, and P.L. Carver Factors influencing the magnitude and clinical significance of drug interactions between azole antifungals and select immunosuppressants Pharmacotherapy 26 2006 1730 1744 (Pubitemid 44885328)
57. H. Leather, R.M. Boyette, L. Tian, and J.R. Wingard Pharmacokinetic evaluation of the drug interaction between intravenous itraconazole and intravenous tacrolimus or intravenous cyclosporin A in allogeneic hematopoietic stem cell transplant recipients Biol Blood Marrow Transplant 12 2006 325 334 (Pubitemid 43273718)
58. A.S. Mathis, N.K. Shah, and G.S. Friedman Combined use of sirolimus and voriconazole in renal transplantation: a report of two cases Transplant Proc 36 2004 2708 2709 (Pubitemid 40036818)
59. C.A. Sable, B.Y. Nguyen, J.A. Chodakewitz, and M.J. DiNubile Safety and tolerability of caspofungin acetate in the treatment of fungal infections Transpl Infect Dis 4 2002 25 30 (Pubitemid 34786821)
60. P.H. Chandrasekar, and J.D. Sobel Micafungin: a new echinocandin Clin Infect Dis 42 2006 1171 1178
61. P.K. Linden, K. Coley, P. Fontes, J.J. Fung, and S. Kusne Invasive aspergillosis in liver transplant recipients: outcome comparison of therapy with amphotericin B lipid complex and a historical cohort treated with conventional amphotericin B Clin Infect Dis 37 2003 17 25 (Pubitemid 36836640)
62. J. Fortun, P. Martín-Dávila, M.A. Sánchez, V. Pintado, M.E. Álvarez, and A. Sánchez-Sousa Voriconazole in the treatment of invasive mold infections in transplant recipients Eur J Clin Microbiol Infect Dis 22 2003 408 413 (Pubitemid 36963113)
63. L.R. Baden, J.T. Katz, J.A. Fishman, C. Koziol, A. DelVecchio, and M. Doran Salvage therapy with voriconazole for invasive fungal infections in patients failing or intolerant to standard antifungal therapy Transplantation 76 2003 1632 1637 (Pubitemid 37549841)
64. J. Maertens, G. Egerer, W.S. Shin, D. Reichert, M. Stek, and S. Chandwani Caspofungin use in daily clinical practice for treatment of invasive aspergillosis: results of a prospective observational registry BMC Infect Dis 10 2010 182
65. D.W. Denning, K.A. Marr, W.M. Lau, D.P. Facklam, V. Ratanatharathorn, and C. Becker Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis J Infect 53 2006 337 349 (Pubitemid 44524711)
66. B.D. Alexander, J.R. Perfect, J.S. Daly, A. Restrepo, A.M. Tobon, and H. Patino Posaconazole as salvage therapy in patients with invasive fungal infections after solid organ transplant Transplantation 86 2008 791 796
67. M.O. Karlsson, I. Lutsar, and P.A. Milligan Population pharmacokinetic analysis of voriconazole plasma concentration data from pediatric studies Antimicrob Agents Chemother 53 2009 935 944
68. A.C. Pasqualotto, and D.W. Denning New and emerging treatments for fungal infections J Antimicrob Chemother 61 Suppl 1 2008 19 30
69. T.J. Walsh, I. Lutsar, T. Driscoll, B. Dupont, M. Roden, and P. Ghahramani Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children Pediatr Infect Dis J 21 2002 240 248 (Pubitemid 34214142)
70. J.R. Perfect, W.E. Dismukes, F. Dromer, D.L. Goldman, J.R. Graybill, and R.J. Hamill Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america Clin Infect Dis 50 2010 291 322
71. F. Dromer, C. Bernede-Bauduin, D. Guillemot, O. Lortholary French Cryptococcosis Study Group Major role for amphotericin B-flucytosine combination in severe cryptococcosis PLoS One 3 2008 e2870
72. H.Y. Sun, B.D. Alexander, O. Lortholary, F. Dormer, G.N. Forrestt, and G.M. Lyon Lipid formulations of amphotericin B significantly improve outcome in solid organ transplant recipients with central nervous system cryptococcosis Clin Infect Dis 49 2009 1721 1728
73. B. Spellberg, T.J. Walsh, D.P. Kontoyiannis, J.E. Edwards Jr., and A.S. Ibrahim Recent advances in the management of mucormycosis: from bench to bedside Clin Infect Dis 48 2009 1743 1751
74. N. Singh, J.M. Aguado, H. Bonatti, G. Forrest, K.L. Gupta, and N. Safdar Zygomycosis in solid organ transplant recipients: a prospective matched case-control study to assess risks for disease and outcome J Infect Dis 200 2009 1002 1011
75. A.S. Ibrahim, T. Gebremariam, Y. Fu, J.E. Edwards Jr., and B. Spellberg Combination echinocandin-polyene treatment of murine mucormycosis Antimicrob Agents Chemother 52 2008 1556 1558 (Pubitemid 351522035)
76. C. Reed, R. Bryant, A. Ibrahim, J. Edwards Jr., S.G. Filler, and R. Goldberg Combination polyene-caspofungin treatment of rhino-orbital-cerebral mucormycosis Clin Infect Dis 47 2008 364 371 (Pubitemid 352009357)
77. J.A. Van Burik, R.S. Hare, H.F. Solomon, M.L. Corrado, and D.P. Kontoyiannis Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases Clin Infect Dis 42 2006 61 65
78. R.N. Greenberg, K. Mullane, J.A. Van Burik, I. Raad, M.J. Abzug, and G. Anstead Posaconazole as salvage therapy for zygomycosis Antimicrob Agents Chemother 50 2006 126 133 (Pubitemid 43042912)
79. A.S. Ibrahim, T. Gebremariam, J.A. Schwartz, J.E. Edwards Jr., and B. Spellberg Posaconazole mono or combination therapy for treatment of murine zygomycosis Antimicrob Agents Chemother 53 2009 772 775
80. A.S. Ibrahim, T. Gebermariam, Y. Fu, L. Lin, M.I. Husseiny, and S.W. French The iron chelator deferasirox protects mice from mucormycosis through iron starvation J Clin Invest 117 2007 2649 2657 (Pubitemid 47494365)
81. C. Reed, A. Ibrahim, J.E. Edwards Jr., I. Walot, and B. Spellberg Deferasirox, an iron-chelating agent, as salvage therapy for rhinocerebral mucormycosis Antimicrob Agents Chemother 50 2006 3968 3969 (Pubitemid 44684931)
82. P. Troke, K. Aguirrebengoa, C. Arteaga, D. Ellis, C. Heath, and I. Lutsar Treatment of scedosporiosis with voriconazole: clinical experience with 107 patients Antimicrob Agents Chemother 52 2008 1743 1750 (Pubitemid 351614668)
83. K.J. Cortez, E. Roilides, F. Quiroz-Telles, J. Meletiadis, C. Antachopoulos, and T. Knudsen Infections caused by Scedosporium spp Clin Microbiol Rev 21 2008 157 197
84. A. Alastruey-Izquierdo, M. Cuenca Eestella, A. Monzón, E. Mellado, and J.L. Rodríguez-Tudela Antifungal susceptibility profile of clinical Fusarium spp. isolates J Antimicrob Chemother 61 2008 805 809 (Pubitemid 351426063)
85. M. Nucci, and E. Anaissie Fusarium infections in immunocompromsied patients Clin Microbiol Rev 30 2007 695 704
86. M. Stanzani, F. Tumietoo, N. Vianelli, and M. Baccarani Update on the treatment of disseminated fusariosis: focus on voriconazole Ther Clin Risk Manage 3 2007 1165 1173
87. L.J. Scott, and D. Simpson Voriconazole: a review of its use in the management of invasive fungal infections Drugs 67 2007 269 278
88. J. Guinea, T. Peláez, S. Recio, M. Torres-Narbona, and E. Bouza In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species Antimicrob Agents Chemother 52 2008 1396 1400 (Pubitemid 351522004)
89. A.C. Pasqualotto, K.O. Thiele, and L.Z. Goldani Novel triazole antifungal drugs: focus on isavuconazole, ravuconazole and albaconazole Curr Opin Investig Drugs 11 2010 165 174
90. P.A. Warn, A. Sharp, G. Morrissey, and D.W. Denning Activity of aminocandin (IP960; HMR3270) compared with amphotericin B, itraconazole, caspofungin and micafungin in neutropenic murine models of disseminated infection caused by itraconazole susceptible and resistant strains of Aspergillus fumigatus Int J Antimicrob Agents 35 2010 146 151
91. J. Pachl, P. Svoboda, F. Jacobs, K. Vandewoude, B. Van der Hoven, P. Spronk Mycograb Invasive Candidiasis Study Goup A randomized, blinded, multicenter trial of lipid-associated amphotericin B alone versus in combination with an antibody-based inhibitor of heat shock protein 90 in patients with invasive candidiasis Clin Infect Dis 42 2006 1404 1413